Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PHIO vs HSDT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
HSDT Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)
HSDT Overall Winner
6-Pillar Tally: PHIO 1 – 4 HSDT (1 Tie)
Matrix Metrics: PHIO 3 – 7 HSDT
As of Nov 20, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Phio Pharmaceuticals Corp. (PHIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PHIO carries a Unified Composite Score of 41.2/100 (SELL) at $0.66 (0.3x Forward P/E, 0.0% operating margin), whereas HSDT carries 47.2/100 (HOLD) at $1.49 (N/M Forward P/E, -1557.5% operating margin).
- Technical & Structure Timing Caution: PHIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.7); meanwhile HSDT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About PHIO vs HSDT
PHIO
Phio Pharmaceuticals Corp. Common Stock
$0.66
-8.25% 1D
Market Cap
$8.5M
TTM Revenue
N/A
Forward P/E
0.3x
Beta / 30D Vol
1.07β · 57% Vol
Unified Composite Score
41.2
SELL
Tech 25.0
Fund 46.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
HSDT
Head-to-Head Winner
Solana Company Class A Common Stock (DE)
$1.49
-10.24% 1D
Market Cap
$104.4M
TTM Revenue
$271M
Forward P/E
N/M
Beta / 30D Vol
2.22β · 60% Vol
Unified Composite Score
47.2
HOLD
Tech 25.0
Fund 58.0
Flow 68.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (PHIO 1 – 4 HSDT)
1. Valuation Multiples
HSDT
Forward P/E
0.3x
N/M
Trailing P/E
0.3x
0.0x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
0.4x
2. Growth & Scale
HSDT
Revenue Growth (YoY)
+0.0%
+382.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$271M
Market Cap
$8.5M
$104.4M
3. Profitability & Quality
HSDT
Gross Margin
N/A
92.8%
Operating Margin
0.0%
-1557.5%
Net Profit Margin
0.0%
2040.4%
Return on Equity (ROE)
-159.0%
52.8%
4. Balance Sheet & Cash Flow
HSDT
Cash Generation (TTM)
-$11M
-$4.21B EBITDA
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$0.72 Book/Sh · -159.0% ROE
$4.38 Book/Sh · 52.8% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PHIO
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
540.7% (85th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Asset Management Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PHIO (3) vs HSDT (7)| Institutional Metric | PHIO | HSDT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $8.5M | $104.4M | HSDT | |
| Trailing P/E Ratio | 0.3x | 0.0x | HSDT | |
| Forward P/E Ratio | 0.3x | N/M | PHIO | |
| Revenue Growth (YoY) | +0.0% | +382.1% | HSDT | |
| Operating Margin (TTM) | 0.0% | -1557.5% | PHIO | |
| Net Profit Margin | 0.0% | 2040.4% | HSDT | |
| Return on Equity (ROE) | -159.0% | 52.8% | HSDT | |
| 52-Week Range Position | 1% ($1–$2) | 10% ($1–$4) | HSDT | |
| Beta / 30D Volatility | 1.07β · 57% Vol | 2.22β · 60% Vol | PHIO | |
| Unified Institutional Score | 41.2 / 100 (SELL) | 47.2 / 100 (HOLD) | HSDT | |
| Trailing 12M Revenue (USD) | N/A | $271M | Scale | |
| Gross Profit Margin (TTM) | N/A | 92.8% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 0.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$11M ($0.72 Book/Sh · -159.0% ROE) | -$4.21B EBITDA ($4.38 Book/Sh · 52.8% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PHIO +9.26 pp
3M Horizon
HSDT +12.28 pp
6M Horizon
HSDT +4.89 pp
1Y Horizon
PHIO +12.85 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PHIO Revenue | HSDT Revenue | PHIO Op. Margin | HSDT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $0M | -5336.2% | -5580.5% | PHIO |
| FY2019 | $0M | $0M | -42795.2% | -1604.0% | HSDT |
| FY2020 | N/A | $0M | N/A | -2176.4% | HSDT |
| FY2021 | N/A | $0M | N/A | -3679.9% | HSDT |
| FY2022 | N/A | $0M | N/A | -1994.3% | HSDT |
| FY2023 | N/A | $0M | N/A | -2054.2% | HSDT |
| FY2024 | N/A | $0M | N/A | -2673.7% | HSDT |
| FY2025 | N/A | $0M | N/A | -44496.4% | HSDT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
PHIO
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PHIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
HSDT
BREAKDOWN
Current IV
540.7%
IV Percentile
85th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact HSDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
PHIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
HSDT Moat Profile
High-Margin Pricing Power Moat
Asset Management Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ PHIO vs HSDT Key Questions & Quantitative Answers
As of Nov 20, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Phio Pharmaceuticals Corp. (PHIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PHIO carries a Unified Composite Score of 41.2/100 (SELL) at $0.66 (0.3x Forward P/E, 0.0% operating margin), whereas HSDT carries 47.2/100 (HOLD) at $1.49 (N/M Forward P/E, -1557.5% operating margin). Technical & Structure Timing Caution: PHIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.7); meanwhile HSDT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
HSDT leads the Growth & Scale pillar: PHIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with HSDT at +382.1% YoY revenue growth and +0.0% YoY earnings growth on $271M TTM revenue (92.8% gross margin, -1557.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PHIO cumulative revenue shifted N/A while HSDT shifted N/A. In operating R&D and SG&A reinvestment, PHIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for HSDT.
HSDT screens cheaper on headline valuation multiples. PHIO trades at 0.3x Forward P/E, 0.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas HSDT trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and 0.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PHIO (-159.0% ROE) versus HSDT (52.8% ROE) capital efficiency.
In options market volatility and institutional positioning, PHIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.07β · 57% Vol realized risk). By comparison, HSDT carries 540.7% implied volatility (85th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.22β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
HSDT vs PHIO · Reverse Pair
HSDT vs QNRX
· Sector Peer
HSDT vs NUWE
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal